<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109499</url>
  </required_header>
  <id_info>
    <org_study_id>GV-003.001</org_study_id>
    <nct_id>NCT00109499</nct_id>
  </id_info>
  <brief_title>Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)</brief_title>
  <official_title>An Open-label, Phase I, Single Administration, Dose- Escalation Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenVec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenVec</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety of AdGVPEDF.11D when given to&#xD;
      patients with &quot;wet&quot; age-related macular degeneration (AMD). AdGVPEDF.11D is a replication&#xD;
      deficient (E1, E3 and E4 deleted) adenovirus vector containing the gene for the PEDF (pigment&#xD;
      epithelium-derived factor) protein. PEDF is a protein that naturally exists in the human eye,&#xD;
      but whose levels are altered in diseases characterized by ocular neovascularization like AMD.&#xD;
      The PEDF protein is known to have anti-angiogenic effects or, in other words, it has the&#xD;
      ability to inhibit growth of new blood vessels.&#xD;
&#xD;
      AdGVPEDF.11D will be delivered once via intravitreal injection into one eye. The injected eye&#xD;
      will be the eye with the worst visual acuity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AdGVPEDF.11D</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 50 years;&#xD;
&#xD;
          -  Severe neovascular AMD in at least one eye responsible for a best corrected vision of&#xD;
             20/200 or worse in the study eye (if both eyes have neovascular AMD and equal visual&#xD;
             acuity scores, the study eye will be determined by the investigator);&#xD;
&#xD;
          -  Best corrected visual acuity in the fellow eye must be equal to or better than the&#xD;
             study eye;&#xD;
&#xD;
          -  Fluorescein angiography of the study eye must show evidence of a leaking subfoveal&#xD;
             choroidal neovascular lesion. The subfoveal component must consist of CNV (choroidal&#xD;
             neovascularization), blood or fibrosis. The total size of the lesion must be â‰¤12 MPS&#xD;
             disc areas. The presence of a leaking subfoveal choroidal neovascular lesion will be&#xD;
             evaluated by the investigator at the clinical site to determine patients' eligibility.&#xD;
&#xD;
          -  Must not be candidates for (including patients who have had treatment with either&#xD;
             modality in the past and are no longer candidates) or must have refused treatment with&#xD;
             subfoveal laser photocoagulation or PDT (photodynamic therapy);&#xD;
&#xD;
          -  Informed consent;&#xD;
&#xD;
          -  Able to comply with protocol requirements including follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver enzymes &gt; 2 x ULN (ALT, AST, bilirubin);&#xD;
&#xD;
          -  Clinical evidence of active infection of any type, including adenovirus, hepatitis A,&#xD;
             B, or C virus or HIV virus;&#xD;
&#xD;
          -  Other treatment for AMD in the study eye within the last twelve weeks prior to Day 1;&#xD;
&#xD;
          -  Other experimental medications within the last four weeks prior to Day 1;&#xD;
&#xD;
          -  Significant retinal disease other than neovascular AMD, such as diabetic retinopathy&#xD;
             or retinal vascular occlusion;&#xD;
&#xD;
          -  Significant non-retinal disease such as ocular atrophy;&#xD;
&#xD;
          -  Cataract or other significant media opacity that might compromise examination and&#xD;
             photography of the posterior segment;&#xD;
&#xD;
          -  Other causes of choroidal neovascularization such as pathologic myopia ( &gt; 8&#xD;
             diopters), ocular histoplasmosis or angioid streaks;&#xD;
&#xD;
          -  Evidence of inflammation (grade 1 or higher) in the anterior and/or posterior&#xD;
             chambers;&#xD;
&#xD;
          -  Cataract surgery or submacular surgery within 3 months;&#xD;
&#xD;
          -  Prior ocular treatment with radiation;&#xD;
&#xD;
          -  Known allergy to fluorescein;&#xD;
&#xD;
          -  Abnormal prothrombin or partial thromboplastin time ( &gt; 1.5 X ULN) or anticoagulant&#xD;
             therapy that cannot be withheld for treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Transplantation Laboratory</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-4682</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA - Jules Stein Eye Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Eye Microsurgical Institute, Inc.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kresge Eye Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>April 28, 2005</study_first_submitted>
  <study_first_submitted_qc>April 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2005</study_first_posted>
  <last_update_submitted>May 11, 2011</last_update_submitted>
  <last_update_submitted_qc>May 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paul Fischer, PhD</name_title>
    <organization>GenVec</organization>
  </responsible_party>
  <keyword>Wet Age-Related Macular Degeneration</keyword>
  <keyword>Age-Related Maculopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

